TY - JOUR. T1 - Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation. AU - ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation. AU - Yoshimitsu, Makoto. AU - Tanosaki, Ryuji. AU - Kato, Koji. AU - Ishida, Takashi. AU - Choi, Ilseung. AU - Takatsuka, Yoshifusa. AU - Fukuda, Takahiro. AU - Eto, Tetsuya. AU - Hidaka, Michihiro. AU - Uchida, Naoyuki. AU - Miyamoto, Toshihiro. AU - Nakashima, Yasuhiro. AU - Moriuchi, Yukiyoshi. AU - Nagafuji, Koji. AU - Miyazaki, Yasuhiko. AU - Ichinohe, Tatsuo. AU - Takanashi, Minoko. AU - Atsuta, Yoshiko. AU - Utsunomiya, Atae. N1 - Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.. PY - 2017/11/16. Y1 - 2017/11/16. N2 - Disease status at allogeneic hematopoietic cell transplantation (HCT) is an important pretransplant prognostic factor of HCT in adult T cell leukemia/lymphoma (ATL); however, other ...
Response rate defined as the proportion of responders relative to the total population and its exact 95% confidence interval were calculated for best overall response.. The antitumor response criteria (Complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD)) were created based on the criteria for non-Hodgkins lymphoma and chronic lymphocytic leukemia provided in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as well as the criteria for non-Hodgkins lymphoma by the Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG).Overall Response (OR)= CR + PR. ...
Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell lymphoma caused by human T-cell leukemia/lymphoma virus type 1 (HTLV-1). ATLL occurs in approximately 3%-5% of HTLV-1 carriers during their lifetime and follows a heterogeneous clinical course. The Shimoyama classification has been frequently used for treatment decisions in ATLL patients, and antiviral therapy has been reportedly promising, particularly in patients with indolent type ATLL; however, the prognosis continues to be dismal for patients with aggressive-type ATLL. Recent efforts to improve treatment outcomes have been focused on the development of prognostic stratification and improved dosage, timing, and combination of therapeutic modalities, such as antiviral therapy, chemotherapy, allogeneic hematopoietic stem cell transplantation, and molecular targeted therapy.
An epidemiological study was performed in French Guiana population 115,000 to determine the prevalence and incidence of adult T-cell leukemia/lymphoma ATL associated with human T-cell leukemia/lymphoma virus type I HTLV-I. From January 1990 to December 1993, all suspected cases of ATL were enrolled in this study, and their clinical,...
Acute lymphoblastic leukemia (ALL) is the commonest childhood malignancy,1 and a major cause of morbidity and mortality from hematopoietic malignancies in adults. While the outcome of treatment for ALL in children is generally favorable, with cure rates exceeding 80%, this is not the case in adults, given that relapse occurs in the majority of patients and carries a poor prognosis. Moreover, improvements in the outcome of therapy of T-lineage ALL, which accounts for approximately 20% of cases of ALL, have lagged behind those of B-progenitor ALL. Consequently, there is great interest in identifying clinical, laboratory and genetic markers that may distinguish patients likely to be cured, who require less intensive treatment, from patients at high risk of relapse, who require aggressive or novel therapies.. From the genetic standpoint, T-lineage ALL is a heterogeneous disease and comprises a number of different subtypes harboring a range of sentinel chromosomal rearrangements, DNA copy number ...
Wilks, R., Hanchard, B., Morgan, O., Williams, E., Cranston, B., Smith, M., ... Manns, A. (1996). Patterns of HTLV-1 infection among family members of patients with adult t-cell leukemia/lymphoma and HTLV-1 associated myelopathy/tropical spastic paraparesis. International Journal of Cancer, 65(2), 272-273. DOI: 10.1002/(SICI)1097-0215(19960117)65:2,272::AID-IJC23,3.0.CO;2-E ...
Purpose: Cell adhesion molecule 1 (CADM1), initially identified as a tumor suppressor gene, has recently been reported to be ectopically expressed in primary adult T-cell leukemia-lymphoma (ATL) cells. We incorporated CADM1 into flow cytometric analysis to reveal oncogenic mechanisms in human T-cell leukemia virus type I (HTLV-1) infection by purifying cells from the intermediate stages of ATL development. Experimental Design: We isolated CADM1- and CD7-expressing peripheral blood mononuclear cells of asymptomatic carriers (ACs) and ATLs using multi-color flow cytometry. FACS-sorted subpopulations were subjected to clonal expansion and gene expression analysis. Results: HTLV-1-infected cells were efficiently enriched in CADM1+ subpopulations (D, CADM1posCD7dim; and N, CADM1posCD7neg). Clonally expanding cells were detected exclusively in these subpopulations in ACs with high proviral load, suggesting that the appearance of D and N could be a surrogate marker of progression from AC to early ATL. ...
Phillips et al identified prognostic risk groups for patients with HTLV-1-associated adult T-cell Leukemia/Lymphoma. This can help to identify a patient who may benefit from more aggressive management. The authors are from Columbia University and multiple cancer centers in New York.
Adult T-Cell Leukemia/Lymphoma (ATL): overexpression of Programmed Death Ligand 1 (PD-L1) contributes to immune evasion - presentation at the AACR 2017 annual meeting
Adult T-cell leukemia-lymphoma (ATL), a highly aggressive peripheral T-cell malignancy caused by human T-cell lymphotropic virus type I, is resistant to conventional chemotherapies and therefore carries a very poor prognosis. The observation that CC chemokine receptor 4 (CCR4) is expressed on ATL tumor cells prompted the development of KW-0761, a next-generation humanized anti-CCR4 monoclonal antibody with a defucosylated Fc region, which enhances antibody-dependent cellular cytotoxicity. Preclinical studies using KW-0761 demonstrated robust antitumor responses, and a phase I clinical trial showed preliminary potent activity against ATL in patients. In a multicenter, single-arm phase II study, Ishida and colleagues investigated the efficacy, pharmacokinetic profile, and safety of KW-0761 monotherapy in patients with relapsed CCR4-positive ATL (acute, lymphoma, or unfavorable chronic type) who had failed one or more prior chemotherapy regimens. The 2 most common treatment-related adverse events, ...
February 8, 2018 N Engl J Med 2018; 378:529-538 DOI: 10.1056/NEJMoa1704827 BACKGROUND Human T-lymphotropic virus type 1 (HTLV-1) causes the debilitating neuroinflammatory disease HTLV-1-associated myelopathy-tropical spastic paraparesis (HAM-TSP) as well as adult T-cell leukemia-lymphoma (ATLL). In patients with HAM-TSP, HTLV-1 infects mainly CCR4+ T cells and induces functional changes, ultimately causing chronic spinal cord inflammation.…
Adult T-cell leukemia-lymphoma (ATL) and its causative agent, human T-cell leukemia virus type 1 (HTLV-1), are endemic in Southwestern Japan, the Caribbean islands, Central/South America, and...
Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W Jr, OMahony D, Janik JE, Bittencourt AL, Taylor GP, Yamaguchi K, Utsunomiya A, Tobinai K, Watanabe T. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009 Jan 20;27(3):453-9. doi: 10.1200/JCO.2008.18.2428. Epub 2008 Dec 8. ...
Background HTLV-I is associated with the development of an aggressive form of lymphocytic leukemia known as adult T-cell leukemia/lymphoma (ATLL). A major obstacle for effective treatment of ATLL resides in the genetic diversity of tumor cells and their ability to acquire resistance to chemotherapy regimens. As a result, most patients relapse and current therapeutic approaches still have limited long-term survival benefits. Hence, the development of novel approaches is greatly needed.. Methods In this study, we found that a small molecule inhibitor of poly (ADP-ribose) polymerase (PARP), PJ-34, is very effective in activating S/G2M cell cycle checkpoints, resulting in permanent cell cycle arrest and reactivation of p53 transcription functions and caspase-3-dependent apoptosis of HTLV-I-transformed and patient-derived ATLL tumor cells. We also found that HTLV-I-transformed MT-2 cells are resistant to PJ-34 therapy associated with reduced cleaved caspase-3 activation and increased expression of ...
Adult T-cell leukemia/lymphoma (ATLL) is a malignancy derived from T cells infected with human T-cell leukemia virus type 1 (HTLV-1), and it is known to be resistant to standard anticancer therapies. Indole-3-carbinol (I3C), a naturally occurring component of Brassica vegetables such as cabbage, broccoli and Brussels sprout, is a promising chemopreventive agent as it is reported to possess antimutagenic, antitumorigenic and antiestrogenic properties in experimental studies. The aim of this study was to determine the potential anti-ATLL effects of I3C both in vitro and in vivo. In the in vitro study, I3C inhibited cell viability of HTLV-1-infected T-cell lines and ATLL cells in a dose-dependent manner. Importantly, I3C did not exert any inhibitory effect on uninfected T-cell lines and normal peripheral blood mononuclear cells. I3C prevented the G1/S transition by reducing the expression of cyclin D1, cyclin D2, Cdk4 and Cdk6, and induced apoptosis by reducing the expression of XIAP, survivin and Bcl-2,
Approach provides a more sensitive, less expensive assessment of relapse potential.. T-lineage acute lymphoblastic leukemia/lymphoma (T-ALL) is an aggressive blood cancer that accounts for 20% to 30% of all acute leukemia. Choosing the correct treatment for a patient is difficult, with some suffering needless side effects from overtreatment and others facing the possibility of relapse because of insufficient treatment.. Harlan Robins, PhD, a computational biologist at Fred Hutchinson Cancer Research Center (Seattle, WA), and colleagues evaluated high-throughput sequencing (HTS) of lymphoid receptor genes as a way to diagnose T-ALL and assess patients for minimal residual disease (MRD), in which leukemia cells can still be detected in the bone marrow using sensitive tests. Their study was published this month in Science Translational Medicine.. The current standard in the United States for assessing MRD is multiparametric flow cytometry; real-time quantitative PCR is another option. However, ...
Adult T-cell leukemia/lymphoma What every physician needs to know: Adult T-cell leukemia/lymphoma (ATL) is a distinct subtype of mature or peripheral T-cell lymphomas associated with the human T-cell lymphotrophic virus type 1 (HTLV-1). HTLV-1 is a human retrovirus that is endemic in certain parts of the world, including the northern and southern islands of Japan,…. ...
CREST. The accurate identification of structural variations using whole-genome DNA sequencing data generated by next-generation sequencing technology is extremely difficult. To address this challenge, we have developed CREST, an algorithm that uses sequencing reads with partial alignments to the reference human genome (so-called soft-clipped reads) to directly map the breakpoints of somatic structural variations. We applied CREST to paired tumor/normal whole genome sequencing data from five cases of T-lineage acute lymphoblastic leukemia (T-ALL). A total of 110 somatic structural variants were identified, ,80% of which were validated by genomic PCR and Sanger sequencing. The validated structural variants included 31 inter-chromosomal translocations, 19 intra-chromosomal translocations, one inversion, 22 deletions and 16 insertions. A comparison of the results generated with CREST to those obtained using the traditional paired-end discordant mapping methods demonstrate CREST to have a much higher ...
T-lineage acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic cancer in which novel more effective antileukemic drugs are needed for the treatment of patients with chemotherapy resistant disease.
My research area is Molecular Virology and specifically relates to the investigation of the pathogenesis of the human retroviruses human T cell leukemia viruses types 1 and 2 (HTLV-1 and HTLV-2, respectively). HTLV-1 causes adult T cell leukemia/lymphoma (ATLL) and chronic inflammatory disorders while HTLV-2 infection is not linked with specific virus related diseases. One key question that still remains unanswered despite intensive research in this area over the past 35 years is why HTLV-1 gives rise to disease while its closely related counter part HTLV-2 is not clearly associated with cancer development. The identification and characterization of key virus/host interactions that contribute to ATLL in individuals infected with HTLV-1 but not HTLV-2 has been the focus of much my HTLV research to date. The overall goal of such work is not only to provide insights into the different clinical outcomes of HTLV infections but also to identify and characterize key cellular players in ATLL ...
1578 The Adenomatous Polyposis Coli (APC) gene is a tumor suppressor gene which is associated with both familial and sporadic cancer. Aberrant methylation of the APC promoter 1A which inactives the APC gene occurs in colorectal tumors as well as many other kinds of cancers. We investigated whether the same mechanism occurs in adult T-cell leukemia/lymphoma (ATL) by analyzing 31 DNA samples from 30 ATL patients and 4 ATL cell lines. APC promoter methylation was found in 15 of 31 (48 %) primary samples, and 2 of 4 (50 %) ATL cell lines. Moreover, methylation of the APC gene occured more frequently in acute ATL (12/21) (57 %) than chronic ATL (1/8) (13 %) (P=0.03). APC promoter was not methylated in any of ten peripheral blood samples from normal individuals. APC was expressed in the normal peripheral blood samples, but not in the APC-methylated ATL cell line ST1. Demethylation with 5-Azacytidine treatment restored APC expression in the ST1 cell line. Our data show for the first time that ...
Adult T-cell leukemia/lymphoma (ATL) is a highly aggressive T-cell malignancy. This study was designed to explore the expression and functional significance of microRNA (miR)-212 in ATL. The expression of miR-212 in human ATL tissues and cell lines were investigated. Gain-of-function experiments were carried out to determine the roles of miR-212 in cell proliferation, tumorigenesis, cell cycle progression, and apoptosis. We also identified and functionally characterized the target genes of miR-212 in ATL cells. Compared with normal lymph node biopsies, lymphoma samples from ATL patients displayed underexpression of miR-212 (p=0.0032). Consistently, miR-212 was downregulated in human ATL cell lines, compared with normal T lymphocytes. Restoration of miR-212 significantly (p,0.05) inhibited ATL cell proliferation and tumorigenesis in mice. Overexpression of miR-212 led to an accumulation of G0/G1-phase cells and a concomitant reduction of S-phase cells. Moreover, enforced expression of ...
Using the clone-specific rearrangement of the T cell receptor gene as the genetic marker of the clonotype, we analyzed the clonal origin of the interleukin 2 (IL-2)-dependent human T-lymphotrophic virus I (HTLV-I)-positive T cell lines established from various adult T cell leukemia (ATL) patients. From a patient with chronic ATL, whose leukemic cells proliferated in vitro in response to IL-2, we repeatedly established leukemic T cell clones having the same rearrangement profile of the T beta chain gene as the leukemic cells. By contrast, established cell lines from acute ATL patients had different beta chain gene rearrangements from those of the leukemic cells. These HTLV-I+ T cell lines might not be the direct progeny of the leukemic cells, but that of T cells infected either in vivo or in vitro. These IL-2-reactive nonleukemic T cells might have been selected in vitro, because their leukemic cells failed to respond to IL-2, despite the expression of IL-2 receptor. The analysis of the T cell ...
Editorial Note: HTLV agents are retroviruses that have recently been associated with certain types of adult T-cell lymphoreticular neoplasms of man (6). HTLV-1 has been associated with acute T-cell leukemia and a related, but clearly different, viral agent, HTLV-2, with hairy-cell T-cell leukemia. Retroviruses are ribonucleic acid (RNA) viruses containing the enzyme, reverse transcriptase, which allows production of a deoxyribonucleic acid (DNA) copy of their RNA genome. The DNA copy can then be integrated into the genome of the cell. Infections with retroviruses other than HTLV have been associated with a variety of neoplastic diseases in animals including chickens, cats, cattle and gibbons. The feline retrovirus also causes immune suppression. HTLV agents are the only presently known retroviruses associated with human diseases. Clinically, however, the diseases previously associated with HTLV in endemic areas do not resemble AIDS. Infections are thought rarely to result in malignancies. HTLV ...
To our knowledge, this is the most extensive study of DNMT3A-mutated T-ALL yet reported. Our targeted NGS approach allowed comprehensive assessment of genotype across the entire DNMT3A locus, along with the prevalence of co-occurring genetic alterations. Our data additionally benefit from the analysis of a large cohort of patients who were uniformly treated as part of the GRAALL-2003 and -2005 studies, thereby allowing rigorous outcome comparisons between mutated and wild-type cases.. Some of our results were expected, and the findings that DNMT3A mutations are more commonly present in older patients and genotypically immature leukemias are consistent with previously published data.9,11-13 We did not, however, observe increased rates of ETP-ALL immunophenotype, as might have been predicted. We did not detect a clear association with any other genetically-defined subgroup, and there was no link to increased HOXA expression, which we have previously shown to predict outcome in immature ...
T-cell leukemia/lymphoma 6 (TCL6), transcript variant TCL6a2, full length, with N-terminal HIS tag, expressed in E. coli, 50ug, 50 µg.
Buy Two Decades of Adult T-Cell Leukemia and HTLV-I Research by Kazuo Sugamura, Takashi Uchiyama from Waterstones today! Click and Collect from your local Waterstones or get FREE UK delivery on orders over £20.
A Lack of Cellular Senescence, Formation of Microenvironment, and Role of Soluble CD30 in Development of Adult T-Cell Leukemia/Lymphoma Abstract.
Mutations in the zinc finger gene PHF6 are seen in approximately 20% of adult T-cell acute lymphoblastic leukemias and 3% of adult acute myeloid leukemias. The notable absence of PHF6 mutations in B-cell lineage malignancies ...
Overexpression or hyper-activation of Cdc20 has been observed in a variety of human cancers. In adult T-cell leukemia (ATL) patients, the viral oncoprotein Tax...
23] Inagaki A, Ishida T, Ishii T, Komatsu H, Iida S, Ding J, Yonekura K, Takeuchi S, Takatsuka Y, Utsunomiya A, Ueda R. Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors. Int J Cancer 2006;15;118:3054-3061 http://dx.doi.org/10.1002/ijc.21688[Crossref ...
This is an open label phase 1b/2a study of patients with relapsed/refractory B- and T-cell lymphomas who are treated in a 3+3 design.
Bortezomib 1.0 mg/m2 IV Days 1-4. Etoposide 50 mg/m2/d 96 hour CIVI on Days 1-4. Vincristine 0.4 mg/m2/d 96 hour CIVI on Days 1-4. Doxorubicin 10 mg/m2/d 96 hour CIVI on Days 1-4. Prednisone 60 mg/m2/d PO on Days 1-5. Cyclophosphamide 375 mg/m2 IV on Day 5. Raltegravir 400 mg PO BID every day starting with cycle 2 therapy for the entire duration of the cycle.. Cycles will be repeated every 21-28 days for 2 cycles beyond best response, or a maximum of 6 cycles.. ...
Looking for online definition of Adult T-cell leukemia/lymphoma in the Medical Dictionary? Adult T-cell leukemia/lymphoma explanation free. What is Adult T-cell leukemia/lymphoma? Meaning of Adult T-cell leukemia/lymphoma medical term. What does Adult T-cell leukemia/lymphoma mean?
In this study, we aimed to identify somatic structural variation of T-cell acute lymphoblastic leukemias (T-ALLs_ from patient-derived xenografts (PDX) at the single-cell level. For this purpose, we performed strand-specific single-cell sequencing of PDX-derived T-ALL relapse samples from two juvenile patients (P1, P33). To validate structural variation detected via scTRIP, we profiled whole exome sequencing (WES) data from P33 (samples taken during initial disease, remission, relapse), and mate-pair sequencing data from P1 (relapse). ...
If you are a society or association member and require assistance with obtaining online access instructions please contact our Journal Customer Services team ...
Fanconi anemia (FA) is an autosomal recessive disease characterized by pancitopenia, congenital malformations, predisposition to cancers and chromosomal instability. We report the clinical and molecular features of a patient initially identified as a potential FA case only because of chemotherapy toxicity during the treatment of a T-lineage acute lymphoblastic leukemia (ALL). Cells from this patient showed a moderate chromosomal instability, increasing sensitivity to DNA crosslinking agents but normal response to ionizing radiation. The analysis of FA proteins demonstrated a marked reduction of FANCD2 (,95%), but normal levels of FANCA or FANCG. Interestingly, this defect was associated with a homozygous missense mutation of FANCD2, resulting in a novel amino-acid substitution (Leu153Ser) at residue Leu153, which is highly conserved through evolution. The FANCD2(L153S) protein, whose reduced expression was not due to impaired transcription, was detected also in its monoubiquitinated form in the ...
In the present study, we have determined p16 deletion status using FISH analysis for a large group of childhood T-ALL cases at diagnosis, and examined the impact of homozygous p16 deletion on in vitro drug resistance and clinical outcome within this group.. The frequency of p16 deletions in this study, 68·4%, is in agreement with the published data (Hebert et al, 1994; Fizzotti et al, 1995; Ohnishi et al, 1995; Okuda et al, 1995; Diccianni et al, 1997). The majority of these deletions were homozygous, but 7% had hemizygous deletions, i.e. one allele detectable, and 14% presented a mixture of populations with 0-2 alleles. The detection of this latter group is a further refinement offered by the FISH technique. These hemizygous and mixed population groups are too small to be analysed as separate entities and are hence excluded from the data presented. One could also add these cases to the p16+/+ and/or p16−/- groups. It seems most logical to then place the hemizygously deleted cases in the ...
Exosomes are membrane nano-vesicles secreted by a multitude of cells that harbor biological constituents such as proteins, lipids, mRNA and microRNA. Exosomes can potentially transfer their cargo to other cells, implicating them in many patho-physiological processes. Mesenchymal stem cells (MSCs), residents of the bone marrow and metastatic niches, potentially interact with cancer cells and/or their derived exosomes. In this study, we investigated whether exosomes derived from adult T-cell leukemia/lymphoma (ATL) cells act as intercellular messengers delivering leukemia-related genes that modulate the properties of human MSCs in favor of leukemia. We hypothesized that the cargo of ATL-derived exosomes is transferred to MSCs and alter their functional behavior to support the establishment of the appropriate microenvironment for leukemia. We showed that both ATL cells (C81 and HuT-102) and patient-derived cells released Tax-containing exosomes. The cargo of HuT-102-derived exosomes consisted of miR-21,
About 13% to 15% of children with ALL have T-cell ALL. This type of leukemia affects boys more than girls, and generally affects children at an older age than B-cell ALL does. It is often associated with an enlarged thymus (which can sometimes cause breathing difficulty) and with early spread to the cerebrospinal fluid (the fluid that surrounds the brain and spinal cord).. ...
Wet-lab validated real-time PCR primer assays for your biological pathway of interest. Select your gene target of interest using an interactive pathway map, and select your plate.
The case and the entity will be discussed at the upcoming 2014 Dermpedia Comprehensive Review of Cutaneous Hematopathology in Scottsdale, AZ.. ...
1. Létourneau S, et al. IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. Clin Immunol. 2009; 123:758-62.. 2. De Totero D, et al. Expression of the IL2 receptor alpha, beta and gamma chains in hairy cell leukemia. Leuk Lymphoma. 1994; 104:412-9.. 3. Qayyum S, et al. Adult T-Cell Leukemia/Lymphoma. Archives of Pathology & Lab Med. 2014; 138:282-6.. http://www.cellmarque.com/Cell ...
Definition of Adult T-cell lymphoma with photos and pictures, translations, sample usage, and additional links for more information.
We have tested a panel of eight CCR7-function scAbs for their ability to block binding of CCR7 ligand binding, and downstream signaling events (Ca2+mobilization, transmigration), and have identified a subset that can block CCR7 activation, and receptor-mediated binding to ligand in vitro, with an EC50 of 1.89nM to 5.49nM. At a 1 µM concentration, our top 2 scAbs blocked calcium mobilization in Chem-1 CCR7 expressing cells. In the presence of the EC50 concentration for each antibody, we have identified a single candidate scAb that successfully blocked transmigration of primary human T-ALL across an HBEC monolayer. At present studies are ongoing to determine if these antibodies can prevent breech of the blood brain barrier in vivo. ...
The TAL-1 gene is located on chromosome 1p32. In about 20% of T-cell acute lymphoblastic leukemias (T-ALL), this gene is disrupted in its 5 portion by a site-specific 100-kg deletion and is fused with the 5 part of the SIL gene, to form SIL-TAL-1 chimeric gene.. ...
The purpose of this study is to see how well individuals with Adult T-cell Leukemia or Lymphoma (ATLL) respond to an investigational cancer treatment. This
The Leukemia & Lymphoma Society wrote - Since 1949, LLS has been dedicated to curing leukemia, lymphoma and myeloma The Leukemia & Lymphoma Society (LLS) is the worlds largest voluntary (nonprofit) health organization dedicated to funding blood cancer research and providing education and patient services. The mission of The Leukemia & Lymphoma Society (LLS) is: Cure leukemia, lymphoma, Hodgkins disease and myeloma, and improve the quality of life of patients and their families. Our Vision for 2010-2011 Each year, we move closer to our goal of finding a cure for blood cancer. This year to support our mission, well be focusing on these specific goals: * Continue to fund blood cancer research projects that offer the best chance of accelerating development of new, promising treatment therapies * Give more people with blood cancer access to clinical trials * Give all people with blood cancer--at every stage of their journey--access to the information and services they need to fight and
View mouse Bcl11b Chr12:107910403-108003602 with: phenotypes, sequences, polymorphisms, proteins, references, function, expression
Purpose: Adult T-cell leukemia (ATL) is usually CD25+ and rapidly fatal. Anti-CD25 recombinant immunotoxin LMB-2 had phase 1 activity limited by immunogenicity and rapid growth. To prevent anti-drug antibodies and leukemic progression between cycles, a phase 2 trial was performed with LMB-2 after cyclophosphamide and fludarabine (FC). Experimental Design: ATL patients received FC days 1-3 and 2 weeks later began up to 6 cycles at 3-week intervals of FC days 1-3 followed by LMB-2 30-40 ug/Kg i.v. days 3, 5 and 7. Three different dose levels of FC (F+C) were used, 20+200 (n=3), 25+250 (n=12), and 30+300 mg/m2 (n=2) Results: Of 17 patients enrolled and treated with FC for cycle-1, 15 received subsequent cycle(s) containing LMB-2 and were therefore evaluable for response. Lack of antibody formation permitted retreatment in most patients. Of 10 evaluable leukemic patients receiving 25+250 or 30+300 mg/m2 of FC, there were 6 (60%) complete (CR) and 2 (20%) partial (PR) remissions, and all 5 with ,25% ...